Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.76 |
| ▸ | MAOB | P27338 | 4/20 | 0.66 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5154716 | 0.98 | TAAR1 (0.73) | TAAR1MAOBIDO1HDAC1HDAC8 | |
| SCHEMBL5200498 | 0.94 | TAAR1 (0.73) | TAAR1MAOBIDO1HDAC1HDAC8 | |
| SCHEMBL2094283 | 0.92 | TAAR1 (0.70) | TAAR1MAOBIDO1HDAC1HDAC8 | |
| SCHEMBL2093159 | 0.92 | TAAR1 (0.70) | TAAR1MAOBIDO1HDAC1HDAC8 | |
| SCHEMBL625402 | 0.86 | TAAR1 (1.00) | TAAR1MAOBIDO1 | |
| SCHEMBL28234872 | 0.84 | TAAR1 (0.65) | TAAR1MAOBIDO1HDAC1HDAC8 | |
| Iodide SCHEMBL28689118 | 0.84 | TAAR1 (0.95) | TAAR1MAOBIDO1MIF | |
| Bromide SCHEMBL28801000 | 0.84 | TAAR1 (0.95) | TAAR1MAOBIDO1MIF | |
| Hydrochloric Acid SCHEMBL4369846 | 0.84 | TAAR1 (0.95) | TAAR1MAOBIDO1MIF | |
| SCHEMBL5096895 | 0.83 | TAAR1 (0.63) | TAAR1MAOBIDO1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-7763618-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2010-07-27 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500716-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-3914351-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | Nodthera Limited (GB) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152361-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-07-30 | — | — | WO | disclosed |
| EP-3087060-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015096651-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
| CN-102134214-B | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2013-05-22 | — | — | CN | disclosed |
| EP-0314422-B1 | N-PHENYLALKYLBENZAMIDE FUNGICIDES | DOWELANCO (US) | 1993-07-28 | — | — | EP | disclosed |
| US-4957533-A | THIOAMIDES, AMIDINES | ELI LILLY AND COMPANY (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0314422-A2 | N-phenylalkylbenzamide fungicides | DOWELANCO (US) | 1989-05-03 | — | — | EP | disclosed |
| US-4533655-A | Analgesic dipeptide amides and method of use and compositions thereof | STERLING DRUG INC. (US) | 1985-08-06 | — | — | US | disclosed |
| US-3953458-A | HYPOTENSIVE AGENTS | MARION LABORATORIES, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | PRMT9, SNRPD3, PRDX5 | TAAR1 3878/4885MAOB 1532/4885IDO1 2457/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | TAAR1 2558/4885MAOB 3255/4885IDO1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.